Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?

키워드

참고문헌 (12)

1. Seulki Lee, "Inhibition of PI3K", Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail, beta-catenin pathway, pp.Clinical and Molecular Hepatology, 2020[DOI]
2. Fruman DA, "The PI3K pathway in human disease", Cell, 170, pp.605~635 (2017)
3. Ali K, "Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer", Nature, 510, pp.407~411 (2014)
4. Ko E, "PI3Kδ is a therapeutic target in hepatocellular carcinoma", Hepatology, 68, pp.2285~2300 (2018)
5. Yang Q, "Idelalisib : first-inclass PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma", Clin Cancer Res, 21, pp.1537~1542 (2015)
6. Patel S, "Glycogen synthase kinase-3 and cancer: good cop, bad cop?", Cancer Cell, 14, pp.351~353 (2008)
7. Xu F, "Roles of the PI3K", AKT, Cell Biosci, pp.2020, 10[DOI]
8. Ma J, "In vitro regulation of hepatocellular carcinoma cell viability, apoptosis, invasion, and AEG-1 expression by LY294002", Clin Res Hepatol Gastroenterol, 38, pp.73~80 (2014)
9. Huang KT, "Correlation between tuberous sclerosis complex 2 and glycogen synthase kinase 3 beta levels, and outcomes of patients with hepatocellular carcinoma treated by hepatectomy", Hepatol Res, 44, pp.1142~1150 (2014)
10. Chua HH, "RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma", Hepatology, 62, pp.1480~1496 (2015)
11. Zhang N, "Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma", Cell Death Dis, 9, pp.230.11~ (2018)
12. Cervello M, "Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma", Adv Biol Regul, 65, pp.59~76 (2017)